- 21 September
-
On September 11–17, 2026, Ekaterinburg hosted the International Youth Festival, a large-scale event that brought together 10,000 young leaders from 191 countries. At the festival running under the motto «Follow Your Dream,» the Medsintez Plant presented its exhibition, showcasing the achievements of the Ural pharmaceutical industry in the field of import substitution.
- 18 September
-
The updated clinical guidelines for treatment of ARVI in children took effect on September 2, 2026. The document was developed by leading experts from the Union of Pediatricians of Russia, the Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy (IACMAC), and the Russian Society of Emergency Medical Care and approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation. It fundamentally shifts therapeutic approaches toward enhanced safety and minimal drug burden.
- 14 September
-
On September 3–4, 2026, Nizhny Novgorod hosted the 2nd Regional Endocrinological Congress: Challenges and Prospects of the Volga Region, with the active participation of the Medsintez Plant. As a strategic company, Medsintez Plant has been ensuring Russia's pharmaceutical security for 25 years. Company's exhibition booth showcased a range of hormonal medications for treatment of type 1 and type 2 diabetes, as well as drugs for infertility treatment through the IVF method.
- 04 September
-
More than twenty years ago, the Regiony Rossii (Regions of Russia, RR) magazine witnessed the birth of an innovative pharmaceutical production facility in Novouralsk, which had no analogues in the country. Today, the Medsintez Plant is a strategic asset in terms of national pharmaceutical security, a recognized industry leader, a National Champion, and a winner of prestigious awards. The secret behind the success of the Ural school of pharmaceuticals and biotechnology is explored in this article by RR.
- Home
- Cluster members
- As & Co Pharm group LLC
As & Co Pharm group LLC
The enterprise As & Co Pharm group LLC is the Ural pharmaceutical company Asco Pharm. The company is a portfolio project of the Ural Federal University (UrFU) Innovation Development Fund, UrFU Innovation Infrastructure and INNOPORT startup studio. Asco Pharm has been researching and developing medicines and dietary supplements for over 15 years. The flagship project of the company is the development of an innovative original drug for the prevention and treatment of osteoporosis, which is in the process of going through the necessary clinical and bureaucratic procedures. In this regard, in order to accelerate the commercialization of the project, the company, based on this drug, brought to the market an innovative dietary supplement REOCYTAN Calcium- Magnesium-D3. Even during the research period, the project showed excellent results, opening up a completely new approach in the fight against osteoporosis and calcium deficiency. The drug uses a patented formula that has no analogues in the world and an innovative technology for delivering calcium to bone tissue. The project has received great interest from the scientific community in Russia and abroad. With this project, the company won the largest business accelerator in the Urals of the Ural Federal University in 2018 And in 2020, Reocytan won the prestigious medical innovation competition held by TIPA in South Korea. Asco Pharm's portfolio also includes more than 20 developments at various stages: recovery after strokes and severe brain injuries, tissue repair after injuries or severe pathologies (heart failure, AECB, SARS, COVID, etc.) oncoprophylaxis technology, technology for removal of hepatitis B virus complicated by D, technology for preventing an autoimmune response in pneumonia of various etiologies, a line of products that suppress muscular dystrophy, etc.
The company is planning to bring several more brands to the market in the next few years.
Tel.: +7 (922)-115-30-63
E-mail: info@ascopharm.ru
www.ascopharm.ru
www.reocytan-calcium.com
